Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth

The development of short interfering RNA (siRNA), has provided great hope for therapeutic targeting of specific genes responsible for patholological disorders. However, the poor cellular uptake and bioavailability of siRNA remain a major obstacle to their clinical development and most strategies tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Crombez, Laurence, Morris, May Catherine, Dufort, Sandrine, Aldrian-Herrada, Gudrun, Nguyen, Quan, Mc Master, Gary, Coll, Jean-Luc, Heitz, Frederic, Divita, Gilles
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
RNA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724276/
https://www.ncbi.nlm.nih.gov/pubmed/19483097
http://dx.doi.org/10.1093/nar/gkp451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724276/
https://www.ncbi.nlm.nih.gov/pubmed/19483097
http://dx.doi.org/10.1093/nar/gkp451

Ejemplares similares